

Francesco Puppo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4977664/publications.pdf>

Version: 2024-02-01

70
papers

2,972
citations

172457

29
h-index

175258

52
g-index

72
all docs

72
docs citations

72
times ranked

3829
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Sjögren's syndrome: a systemic autoimmune disease. <i>Clinical and Experimental Medicine</i> , 2022, 22, 9-25. | 3.6 | 115 |
| 2 | In-111 octreotide SPECT/CT in the early diagnosis of pulmonary sarcoidosis: A case report. <i>Radiology Case Reports</i> , 2022, 17, 340-343. | 0.6 | 0 |
| 3 | Distinguishing Features in Systemic Sclerosis Patients with Non-Specific Interstitial Pneumonia and Idiopathic Pulmonary Fibrosis. , 2022, , . | | 0 |
| 4 | Stem cells therapy in acute myocardial infarction: a new era?. <i>Clinical and Experimental Medicine</i> , 2021, 21, 231-237. | 3.6 | 16 |
| 5 | HLA-G in Allergy: Does It Play an Immunoregulatory Role?. <i>Frontiers in Immunology</i> , 2021, 12, 789684. | 4.8 | 3 |
| 6 | Expression of membrane-bound human leucocyte antigen-G in systemic sclerosis and systemic lupus erythematosus. <i>Human Immunology</i> , 2020, 81, 162-167. | 2.4 | 15 |
| 7 | HLA-G Expressing Immune Cells in Immune Mediated Diseases. <i>Frontiers in Immunology</i> , 2020, 11, 1613. | 4.8 | 36 |
| 8 | Diagnosis of an unusual case of idiopathic mediastinal fibrosis by 18F-FDG PET/CT. <i>Radiology Case Reports</i> , 2020, 15, 435-436. | 0.6 | 0 |
| 9 | New York Heart Association class associated with imaging is a prognostic mortality risk predictor in interstitial lung diseases. <i>European Review for Medical and Pharmacological Sciences</i> , 2020, 24, 9012-9021. | 0.7 | 1 |
| 10 | Effects of AntagomiRs on Different Lung Diseases in Human, Cellular, and Animal Models. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3938. | 4.1 | 13 |
| 11 | Emerging role of vitamin D in autoimmune diseases: An update on evidence and therapeutic implications. <i>Autoimmunity Reviews</i> , 2019, 18, 102350. | 5.8 | 186 |
| 12 | Update upon the infection risk in patients receiving TNF alpha inhibitors. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 219-229. | 2.4 | 37 |
| 13 | Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 199-208. | 5.6 | 90 |
| 14 | Ilprost use and medical management of systemic sclerosis-related vasculopathy in Italian tertiary referral centers: results from the PROSIT study. <i>Clinical and Experimental Medicine</i> , 2019, 19, 357-366. | 3.6 | 23 |
| 15 | Immunogenicity of infliximab and adalimumab. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 343-345. | 2.4 | 11 |
| 16 | IL-33/IL-31 Axis in Immune-Mediated and Allergic Diseases. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5856. | 4.1 | 91 |
| 17 | Evaluation of membrane-bound and soluble forms of human leucocyte antigen-G in systemic sclerosis. <i>Clinical and Experimental Immunology</i> , 2018, 193, 152-159. | 2.6 | 11 |
| 18 | Update upon efficacy and safety of etanercept for the treatment of spondyloarthritis and juvenile idiopathic arthritis. <i>Modern Rheumatology</i> , 2018, 28, 417-431. | 1.8 | 30 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Esophageal baseline impedance levels allow the identification of esophageal involvement in patients with systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 569-574. | 3.4 | 5 |
| 20 | HLA-G expression in gastric carcinoma: clinicopathological correlations and prognostic impact. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 473, 425-433. | 2.8 | 27 |
| 21 | The antiphospholipid syndrome: from pathophysiology to treatment. <i>Clinical and Experimental Medicine</i> , 2017, 17, 257-267. | 3.6 | 84 |
| 22 | Behavior of soluble HLA-A, -B, -C and HLA-G molecules in patients with chronic hepatitis C virus infection undergoing pegylated interferon- α and ribavirin treatment: potential role as markers of response to antiviral therapy. <i>Clinical and Experimental Medicine</i> , 2017, 17, 93-100. | 3.6 | 10 |
| 23 | International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritis, etc.) <i>TJ ETQq1 1 0.784314 rgBT /Overlock 11</i> | 5.8 | 107 |
| 24 | Impact of pharmacogenomics upon the therapeutic response to etanercept in psoriasis and psoriatic arthritis. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 1173-1179. | 2.4 | 22 |
| 25 | Immunoregulatory Role of HLA-G in Allergic Diseases. <i>Journal of Immunology Research</i> , 2016, 2016, 1-7. | 2.2 | 19 |
| 26 | Beneficial effects of long-term treatment with bosentan on the development of pulmonary arterial hypertension in patients with systemic sclerosis. <i>Journal of International Medical Research</i> , 2016, 44, 85-89. | 1.0 | 8 |
| 27 | Allergen-driven HLA-G expression and secretion in peripheral blood mononuclear cells from allergic rhinitis patients. <i>Human Immunology</i> , 2016, 77, 1172-1178. | 2.4 | 8 |
| 28 | Vaccine-preventable infections in Systemic Lupus Erythematosus. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 632-643. | 3.3 | 26 |
| 29 | Genetic factors and systemic sclerosis. <i>Autoimmunity Reviews</i> , 2016, 15, 427-432. | 5.8 | 59 |
| 30 | Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety?. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 43-52. | 2.4 | 72 |
| 31 | Efficacy of cilostazol for the treatment of Raynaud's phenomenon in systemic sclerosis patients. <i>Clinical and Experimental Medicine</i> , 2016, 16, 407-412. | 3.6 | 8 |
| 32 | Autoimmune central diabetes insipidus in a patient with ureaplasma urealyticum infection and review on new triggers of immune response. <i>Archives of Endocrinology and Metabolism</i> , 2015, 59, 554-558. | 0.6 | 4 |
| 33 | Infection risk associated with anti-TNF- α agents: a review. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 571-582. | 2.4 | 153 |
| 34 | Multi-antibody composition in lupus nephritis: Isotype and antigen specificity make the difference. <i>Autoimmunity Reviews</i> , 2015, 14, 692-702. | 5.8 | 63 |
| 35 | Potential use of TNF- α inhibitors in systemic sclerosis. <i>Immunotherapy</i> , 2014, 6, 283-289. | 2.0 | 53 |
| 36 | Efficacy and safety of etanercept in chronic immune-mediated disease. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 649-661. | 2.4 | 24 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | TNF- α Gene Polymorphisms: Association with Disease Susceptibility and Response to Anti-TNF- α Treatment in Psoriatic Arthritis. <i>Journal of Investigative Dermatology</i> , 2014, 134, 2503-2509. | 0.7 | 89 |
| 38 | Pharmacogenetics of etanercept: role of TNF- α gene polymorphisms in improving its efficacy. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 1703-1710. | 3.3 | 52 |
| 39 | Influenza and pneumococcal vaccinations of patients with systemic lupus erythematosus: Current views upon safety and immunogenicity. <i>Autoimmunity Reviews</i> , 2014, 13, 75-84. | 5.8 | 76 |
| 40 | Current therapies for the treatment of systemic sclerosis-related pulmonary arterial hypertension: efficacy and safety. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 295-305. | 2.4 | 18 |
| 41 | Pharmacogenetics and Future Therapeutic Scenarios: What Affects the Prediction of Response to Treatment with Etanercept?. <i>Drug Development Research</i> , 2014, 75, S7-S10. | 2.9 | 12 |
| 42 | Free radicals and endothelial dysfunction: Potential positive effects of TNF- α inhibitors. <i>Redox Report</i> , 2013, 18, 95-99. | 4.5 | 55 |
| 43 | Use of leflunomide plus TNF- α inhibitors in rheumatoid arthritis. <i>Expert Opinion on Drug Safety</i> , 2013, 12, 801-804. | 2.4 | 22 |
| 44 | Long-term treatment of rheumatoid arthritis with adalimumab. <i>Open Access Rheumatology: Research and Reviews</i> , 2013, 5, 43. | 1.6 | 11 |
| 45 | Soluble human leukocyte antigen G serum levels in patients with acquired immune deficiency syndrome affected by different disease-defining conditions before and after antiretroviral treatment. <i>Human Immunology</i> , 2011, 72, 712-6. | 2.4 | 12 |
| 46 | Behavior of non-classical soluble HLA class G antigens in human immunodeficiency virus 1-infected patients before and after HAART: Comparison with classical soluble HLA-A, -B, -C antigens and potential role in immune-reconstitution. <i>Clinical Immunology</i> , 2009, 133, 238-244. | 3.2 | 34 |
| 47 | Sublingual immunotherapy reduces soluble HLA-G and HLA-A,-B,-C serum levels in patients with allergic rhinitis. <i>International Immunopharmacology</i> , 2009, 9, 253-257. | 3.8 | 21 |
| 48 | Soluble HLA-G and HLA-A,-B,-C serum levels in patients with allergic rhinitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2008, 63, 1335-1338. | 5.7 | 21 |
| 49 | Behavior of serum human major histocompatibility complex class I antigen levels in human immunodeficiency virus-infected patients during antiretroviral therapy: Correlation with clinical outcome. <i>Human Immunology</i> , 2007, 68, 894-900. | 2.4 | 8 |
| 50 | Emerging biologic drugs for the treatment of rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2005, 4, 537-541. | 5.8 | 51 |
| 51 | Apoptosis of Antigen-Specific T Lymphocytes upon the Engagement of CD8 by Soluble HLA Class I Molecules Is Fas Ligand/Fas Mediated: Evidence for the Involvement of p56 ^{lck} , Calcium Calmodulin Kinase II, and Calcium-Independent Protein Kinase C Signaling Pathways and for NF- κ B and NF-AT Nuclear Translocation. <i>Journal of Immunology</i> , 2005, 175, 7244-7254. | 0.8 | 66 |
| 52 | Induction of interleukin 10 by sublingual immunotherapy for house dust mites: a preliminary report. <i>Annals of Allergy, Asthma and Immunology</i> , 2005, 95, 38-44. | 1.0 | 115 |
| 53 | Increased levels of interleukin-10 in saliva of Sjögren's syndrome patients. Correlation with disease activity. <i>Clinical and Experimental Medicine</i> , 2004, 4, 148-151. | 3.6 | 43 |
| 54 | Soluble HLA-A,-B,-C and G molecules induce apoptosis in T and NK CD8 ⁺ cells and inhibit cytotoxic T _H 1 cell activity through CD8 ligation. <i>European Journal of Immunology</i> , 2003, 33, 125-134. | 2.9 | 338 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Fas, Fas ligand, and transfusion immunomodulation. <i>Transfusion</i> , 2001, 41, 416-418. | 1.6 | 33 |
| 56 | In vitro immunosuppressive activity of soluble HLA class I and Fas ligand molecules: do they play a role in autologous blood transfusion?. <i>Transfusion</i> , 2001, 41, 988-996. | 1.6 | 45 |
| 57 | Increased β 2-microglobulin-free HLA class I heavy chain serum levels in the course of immune responses to viral antigens and to mismatched HLA antigens. <i>Tissue Antigens</i> , 2000, 55, 333-341. | 1.0 | 4 |
| 58 | Soluble β 2-microglobulin-associated and β 2-microglobulin-free HLA class I heavy chain serum levels in interferon- α nonresponder chronic hepatitis C patients. Markers of immune activation, and response to antiviral retreatment. <i>Journal of Clinical Immunology</i> , 2000, 20, 486-490. | 3.8 | 7 |
| 59 | Soluble human MHC class I molecules induce soluble Fas ligand secretion and trigger apoptosis in activated CD8+ Fas (CD95)+ T lymphocytes. <i>International Immunology</i> , 2000, 12, 195-203. | 4.0 | 98 |
| 60 | β 2-microglobulin-free HLA class I heavy chain levels in sera of healthy individuals. Lack of association with β 2-microglobulin-associated HLA class I heavy chain levels and HLA phenotype. <i>Tissue Antigens</i> , 1999, 53, 253-262. | 1.0 | 18 |
| 61 | Determination of soluble HLA-G and HLA-A, -B, and -C molecules in pregnancy. <i>Transplantation Proceedings</i> , 1999, 31, 1841-1843. | 0.6 | 30 |
| 62 | Immunoregulatory role of soluble HLA molecules: a new skin for an old subject?. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 1998, 46, 157-60. | 2.3 | 4 |
| 63 | Quantitative analyses of plasma opsonizing activity and polymorphonuclear cell response during phagocytosis: standardisation of a chemiluminescent method. <i>Apmsis</i> , 1996, 104, 500-508. | 2.0 | 1 |
| 64 | Serum HLA class I antigen levels in allogeneic bone marrow transplantation: a possible marker of acute GVHD. <i>Bone Marrow Transplantation</i> , 1996, 17, 753-8. | 2.4 | 10 |
| 65 | Behavior of soluble HLA class I antigens in patients with chronic hepatitis C during interferon therapy: An early predictor marker of response?. <i>Journal of Clinical Immunology</i> , 1995, 15, 179-184. | 3.8 | 26 |
| 66 | Serum HLA class I antigens: markers and modulators of an immune response?. <i>Trends in Immunology</i> , 1995, 16, 124-127. | 7.5 | 113 |
| 67 | Increased level of serum HLA class I antigens in HIV infection correlation with disease progression. <i>Human Immunology</i> , 1994, 40, 259-266. | 2.4 | 43 |
| 68 | Simple elisa method for the evaluation of soluble hla class i antigens in human serum. <i>Journal of Clinical Laboratory Analysis</i> , 1991, 5, 278-283. | 2.1 | 19 |
| 69 | Major histocompatibility gene products and human immunodeficiency virus infection. <i>Translational Research</i> , 1991, 117, 91-100. | 2.3 | 8 |
| 70 | Systemic sarcoidosis with pituitary adenoma. <i>Journal of Clinical Imaging Science</i> , 0, 12, 32. | 1.1 | 1 |